journal article·2022-01Open access

Thermogels containing sulfated hyaluronan as novel topical therapeutics for treatment of ocular surface inflammation

Duc Dung Nguyen, Li-Jyuan Luo, Jui-Yang Lai

Abstract

The development of long lasting therapeutic agents is critically important for efficient treatment of chronic diseases. We herein report a rational strategy to develop a therapeutic thermogel featured with prolonged anti-inflammatory and corneal-protective effects. Specifically, a hyaluronic acid with different sulfation degrees and an amine-terminated poly(N-isopropylacrylamide) are conjugated to achieve the thermogels. In vitro studies reveal that the thermogels are highly biocompatible to statens seruminstitut rabbit cornea cells and their anti-inflammatory properties are strongly dependent on the sulfation degree. In a rabbit model of ocular inflammation, single-dose topical administration of a thermogel formulation could repair defects in corneal epithelium (∼99% thickness restored), prevent corneal cell apoptosis (∼68.3% cells recovered), and suppress ocular surface inflammation (∼4-fold decrease) for a follow-up period of 7 days. This high treatment efficacy of the thermogel can be attributed to its potent inhibition in selectin-mediated leukocyte infiltration as well as effective corneal protection. These findings show a great promise for topical treatment of ocular inflammation and advancement of ophthalmic formulations using the bioactive thermogel as a therapeutic component that is not rapidly cleared from the eye and thus considerably reduces administration times.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ocular Surface and Contact Lens · Corneal Surgery and Treatments · Proteoglycans and glycosaminoglycans research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (79)

Show source-provided references
1. Blink rate, incomplete blinks and computer vision syndrome10.1097/OPX.0b013e31828f09a7 ↗
2. Aging and dry eye disease10.1016/j.exger.2012.03.020 ↗
3. Advancing the stimuli response of polymer-based drug delivery systems for ocular disease treatment10.1039/D0PY00919A ↗
4. Ageing and the natural history of dry eye disease: a prospective registry-based cross-sectional study10.1016/j.jtos.2020.07.003 ↗
5. The economic burden of dry eye disease in the United States: a decision tree analysis10.1097/ICO.0b013e3181f7f363 ↗
7. Impact of ocular surface symptoms on quality of life in a United States veterans affairs population10.1016/j.ajo.2011.11.030 ↗
8. Analysis of inflammatory cytokines in the tears of dry eye patients10.1097/ICO.0b013e3181a16578 ↗
9. Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment10.1016/j.clae.2017.11.004 ↗
10. Topical cyclosporine A therapy for dry eye syndrome
11. Recent perspectives in ocular drug delivery10.1007/s11095-008-9694-0 ↗
12. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years10.1016/j.ophtha.2005.05.013 ↗
13. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes10.1001/archopht.118.11.1489 ↗
14. Role of Th17 cells in the immunopathogenesis of dry eye disease10.1038/mi.2009.21 ↗
15. Conjunctival T-cell subpopulations in Sjögren’s and non-Sjögren’s patients with dry eye
16. Sjögren’s syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium
17. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren’s syndrome keratoconjunctivitis sicca10.1076/ceyr.19.3.201.5309 ↗
18. Elevated tear interleukin-6 levels in patients with Sjögren’s syndrome10.1016/S0161-6420(98)91236-2 ↗
19. Distribution of conjunctival HLA-DR expression and the pathogenesis of damage in early dry eye10.1097/01.ico.0000157421.93522.00 ↗
20. Strain-related cytokine profiles on the murine ocular surface in response to desiccating stress10.1097/ICO.0b013e318033a729 ↗
21. Dietary lactoferrin alleviates age-related lacrimal gland dysfunction in mice10.1371/journal.pone.0033148 ↗
22. The core mechanism of dry eye disease is inflammation10.1097/ICL.0000000000000042 ↗
23. Evaluation of topical cyclosporine for the treatment of dry eye disease10.1001/archopht.126.8.1046 ↗
24. Corticosteroid-induced glaucoma: a review of the literature10.1038/sj.eye.6701895 ↗
25. TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model10.1038/s41598-017-17869-y ↗
26. Demonstration of P-selectin expression and potential function in human corneal epithelial cells10.1016/j.exer.2018.07.018 ↗
27. Comparison of 0.1%, 0.18%, and 0.3% hyaluronic acid eye drops in the treatment of experimental dry eye10.1089/jop.2018.0032 ↗
28. Effectiveness of sodium hyaluronate eye drops in the treatment of dry eye10.1007/s00417-005-0028-1 ↗
29. Hyaluronic acid in ocular drug delivery10.1016/j.carbpol.2021.118006 ↗
30. Applications of hyaluronic acid in ophthalmology and contact lenses10.3390/molecules26092485 ↗
31. In vitro and in vivo selectin-blocking activities of sulfated lipids and sulfated sialyl compounds10.1093/intimm/10.5.569 ↗
32. Therapeutic effect of sulphated hyaluronic acid, a potential selectin-blocking agent, on experimental progressive mesangial proliferative glomerulonephritis10.1002/path.1209 ↗
33. Sulfated hyaluronic acid, a potential selectin inhibitor, ameliorates experimentally induced crescentic glomerulonephritis10.1159/000081795 ↗
34. Covalent linkage of sulfated hyaluronan to the collagen scaffold Mucograft® enhances scaffold stability and reduces proinflammatory macrophage activation in vivo
35. Modifications of hyaluronan influence the interaction with human bone morphogenetic protein-4 (hBMP-4)10.1021/bm9008827 ↗
36. A gelatin-g-poly(N-isopropylacrylamide) biodegradable in situ gelling delivery system for the intracameral administration of pilocarpine10.1016/j.biomaterials.2011.11.085 ↗
37. Preparation of thermo-responsive and injectable hydrogels based on hyaluronic acid and poly(N-isopropylacrylamide) and their drug release behaviors10.1007/BF03219073 ↗
38. Photoresponsive PEG-anthracene grafted hyaluronan as a controlled-delivery biomaterial10.1021/bm101233m ↗
39. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride10.1167/iovs.07-0720 ↗
40. Mikulicz's disease and Sjogren's syndrome
41. Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes10.1159/000055537 ↗
42. The gene transfection efficiency of thermoresponsive N, N, N-trimethyl chitosan chloride-g-poly (N-isopropyl acrylamide) copolymer10.1016/j.biomaterials.2007.06.033 ↗
43. Stimuli-responsive, biocompatible hydrogel derived from glycogen and poly(N-isopropylacrylamide) for colon targeted delivery of ornidazole and 5-amino salicylic acid10.1039/C6PY01128D ↗
44. Synthesis of functionalized amine oligomers by free-radical telomerization of methyl methacrylate with a peculiar telogen: 2-Aminoethanethiol hydrochloride10.1002/pola.20303 ↗
45. Stimuli-sensitive hydrogel based on N-isopropylacrylamide and itaconic acid for entrapment and controlled release of Candida rugosa lipase under mild conditions10.1155/2014/364930 ↗
46. Novel thermosensitive hydrogel composites based on poly(D,L-lactide-co-glycolide) nanoparticles embedded in poly(N-isopropyl acrylamide) with sustained drug-release behavior10.1002/app.40625 ↗
47. Selective binding of C-6 OH sulfated hyaluronic acid to the angiogenic isoform of VEGF(165)10.1016/j.biomaterials.2015.10.074 ↗
48. Sulphated hyaluronic acids: a chemical and biological characterization10.1002/(SICI)1097-0126(199807)46:3<225::AID-PI45>3.0.CO;2-I ↗
49. Preparation of low-molecular-weight hyaluronic acid by ozone treatment10.1016/j.carbpol.2012.03.081 ↗
50. Production and characterization of bacterial cellulose membranes with hyaluronic acid from chicken comb10.1016/j.ijbiomac.2017.01.077 ↗
51. Thermoresponsive poly(N-isopropylacrylamide-co-dimethylaminoethyl methacrylate) microgel aqueous dispersions with potential antimicrobial properties10.3390/polym11040606 ↗
52. Evaluation of surface charge shift of collagen fibrils exposed to glutaraldehyde10.1038/s41598-018-28293-1 ↗
53. Self-assembled thermoresponsive nanostructures of hyaluronic acid conjugates for osteoarthritis therapy10.1039/C7NR07614B ↗
54. Incorporation of sulfated hyaluronic acid macromers into degradable hydrogel scaffolds for sustained molecule delivery10.1039/C3BM60227C ↗
55. Thermoreversible hyaluronic acid-PNIPAAm hydrogel systems for 3D stem cell culture10.1002/adhm.201800225 ↗
56. Hyaluronan/collagen hydrogels with sulfated hyaluronan for improved repair of vascularized tissue tune the binding of proteins and promote endothelial cell growth10.1002/mabi.201700154 ↗
57. Improvement of the digestibility of sulfated hyaluronans by bovine testicular hyaluronidase: a UV spectroscopic and mass spectrometric study10.1155/2014/986594 ↗
58. Assessment of cytotoxicity of (N-isopropyl acrylamide) and poly(N-isopropyl acrylamide)-coated surfaces10.1186/1559-4106-8-19 ↗
59. Bioengineered human corneal endothelium for transplantation10.1001/archopht.124.10.1441 ↗
60. Cytoprotective effects of hyaluronic acid and carbomer 934P in ocular surface epithelial cells
61. Biocompatibility and enzymatic degradation studies on sulphated hyaluronic acid derivatives10.1016/S0142-9612(97)00089-6 ↗
62. Anti-inflammatory effects of hyaluronan in arthritis therapy: not just for viscosity10.2147/IJGM.S5495 ↗
63. Hyaluronan, a crucial regulator of inflammation10.3389/fimmu.2014.00101 ↗
64. Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea
65. Anti-inflammatory effects of sulfatides in selectin-dependent acute lung injury10.1093/intimm/7.7.1107 ↗
66. The challenge of dry eye diagnosis10.2147/OPTH.S1496 ↗
67. Dry eye with only decreased tear break-up time is sometimes associated with allergic conjunctivitis10.1016/S0161-6420(95)31024-X ↗
68. Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping10.1089/jop.2015.0054 ↗
69. Rose bengal staining as an assessment of ocular surface damage and recovery in dry eye disease-a review10.1016/j.clae.2013.07.008 ↗
70. The diagnosis and management of dry eye: a twenty-five-year review10.1097/00003226-200009000-00009 ↗
71. Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice
72. In vitro measurement of rabbit corneal epithelial thickness using ultrahigh resolution optical coherence tomography10.1111/j.1463-5224.2005.00345.x ↗
73. Apoptosis of ocular surface cells in experimentally induced dry eye10.1167/iovs.02-0581 ↗
74. Research on the stability of a rabbit dry eye model induced by topical application of the preservative benzalkonium chloride
75. Efficacy of osmoprotectants on prevention and treatment of murine dry eye10.1167/iovs.13-12081 ↗
76. Diclofenac protects cultured human corneal epithelial cells against hyperosmolarity and ameliorates corneal surface damage in a rat model of dry eye10.1167/iovs.13-13850 ↗
77. A murine model of dry eye induced by topical administration of erlotinib eye drops
78. Advances in the diagnosis and treatment of dry eye10.1016/j.preteyeres.2020.100842 ↗
79. Sleep deprivation induces dry eye through inhibition of PPARα expression in corneal epithelium10.1167/iovs.18-24504 ↗